Literature DB >> 20231366

ANE syndrome caused by mutated RBM28 gene: a novel etiology of combined pituitary hormone deficiency.

Ronen Spiegel1, Stavit A Shalev, Amin Adawi, Eli Sprecher, Yardena Tenenbaum-Rakover.   

Abstract

OBJECTIVE AND
DESIGN: A homozygous loss-of-function mutation in the gene RBM28 was recently reported to underlie alopecia, neurological defects, and endocrinopathy (ANE) syndrome. The aim of the present study was to characterize the endocrine phenotype of ANE syndrome and to delineate its pathogenesis.
METHODS: Detailed neuroendocrine assessment was performed in five affected male siblings harboring the homozygous p.L351P mutation in RBM28.
RESULTS: All five affected patients, aged 20-39 years, displayed absent puberty, hypogonadism, and variable degrees of short stature. Low IGF1 concentration and a lack of GH response to provocative tests in all siblings were consistent with GH deficiency. Low testosterone and gonadotropin levels with absence or low response to GnRH stimulation indicated hypogonadotropic hypogonadism. ACTH deficiency evolved over time, and glucocorticoid replacement therapy was initiated in four patients. Thyroid analysis showed variable abnormal TSH response to TRH stimulation, suggesting hypothalamic compensated hypothyroidism in four subjects and laboratory hypothyroidism (low free thyroxine) in one patient. Low prolactin levels were shown in one case.
CONCLUSIONS: The endocrine defects characteristic of ANE syndrome are compatible with variable combined anterior pituitary hormone deficiency (CPHD), which evolves gradually over the years, indicating long-term hormonal monitoring. We propose that defects in the cellular Wnt/beta-catenin signaling pathway underlie this endocrinopathy. RBM28 gene defects should be added to the growing list of gene defects associated with syndromic CPHD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20231366     DOI: 10.1530/EJE-10-0077

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  7 in total

Review 1.  Endocrine disorders in Woodhouse-Sakati syndrome: a systematic review of the literature.

Authors:  M Agopiantz; P Corbonnois; A Sorlin; C Bonnet; M Klein; N Hubert; V Pascal-Vigneron; P Jonveaux; T Cuny; B Leheup; G Weryha
Journal:  J Endocrinol Invest       Date:  2014-01-08       Impact factor: 4.256

Review 2.  MicroRNAs and developmental timing.

Authors:  Victor Ambros
Journal:  Curr Opin Genet Dev       Date:  2011-04-29       Impact factor: 5.578

Review 3.  Genetics of Combined Pituitary Hormone Deficiency: Roadmap into the Genome Era.

Authors:  Qing Fang; Akima S George; Michelle L Brinkmeier; Amanda H Mortensen; Peter Gergics; Leonard Y M Cheung; Alexandre Z Daly; Adnan Ajmal; María Ines Pérez Millán; A Bilge Ozel; Jacob O Kitzman; Ryan E Mills; Jun Z Li; Sally A Camper
Journal:  Endocr Rev       Date:  2016-11-09       Impact factor: 19.871

4.  Biallelic splicing variants in the nucleolar 60S assembly factor RBM28 cause the ribosomopathy ANE syndrome.

Authors:  Carson J Bryant; Cláudia F Lorea; Hiram Larangeira de Almeida; Letícia Weinert; Leonardo Vedolin; Filippo Pinto E Vairo; Susan J Baserga
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-11       Impact factor: 11.205

5.  Faulty ribosome biogenesis underlies the ribosomopathy alopecia, neurological defects, endocrinopathy (ANE) syndrome.

Authors:  Jennifer L Gerton
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-15       Impact factor: 11.205

6.  Mapping of leptin and its syntenic genes to chicken chromosome 1p.

Authors:  Eyal Seroussi; Frédérique Pitel; Sophie Leroux; Mireille Morisson; Susanne Bornelöv; Shoval Miyara; Sara Yosefi; Larry A Cogburn; David W Burt; Leif Anderson; Miriam Friedman-Einat
Journal:  BMC Genet       Date:  2017-08-09       Impact factor: 2.797

Review 7.  Uncovering the assembly pathway of human ribosomes and its emerging links to disease.

Authors:  Katherine E Bohnsack; Markus T Bohnsack
Journal:  EMBO J       Date:  2019-05-14       Impact factor: 11.598

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.